Download PDF
Thromb Haemost 2005; 93(05): 914-921
DOI: 10.1160/TH04-08-0554
Platelets and Blood Cells
Schattauer GmbH

Recombinant albumins containing additional peptide sequences smaller than barbourin retain the ability of barbourin-albumin to inhibit platelet aggregation

William P. Sheffield
1   Department of Pathology and Molecular Medicine, McMaster University
2   Canadian Blood Services, Research and Development, Hamilton, Ontario, Canada
,
Brianna Wilson
1   Department of Pathology and Molecular Medicine, McMaster University
,
Louise J. Eltringham-Smith
1   Department of Pathology and Molecular Medicine, McMaster University
,
Sharon Gataiance
1   Department of Pathology and Molecular Medicine, McMaster University
,
Varsha Bhakta
2   Canadian Blood Services, Research and Development, Hamilton, Ontario, Canada
› Author AffiliationsGrant support: This work was supported by Grant-In-Aid T4612 from the Heart and Stroke Foundation of Ontario.
Further Information

Publication History

Received 30 August 2004

Accepted after revision 26 January 2005

Publication Date:
11 December 2017 (online)

    Permissions and Reprints

Summary

The previously described fusion protein BLAH6 (Marques JA et al., Thromb Haemost 2001; 86: 902–8) is a recombinant protein that combines the small disintegrin barbourin with hexahisti-dine-tagged rabbit serum albumin (RSA) produced in Pichia pastoris yeast. We sought to determine: (1) if BLAH6 was immunogenic; and (2) if its barbourin domain could be productively replaced with smaller peptides. Purified BLAH6 was injected into rabbits, and anti-barbourin antibodies were universally detected in plasma 28 days later; BLAH6 was, however, equally effective in reducing platelet aggregation in both naïve and pre-treated rabbits. Thrombocytopenia was not observed, and complexing BLAH6 to αIIbβ3 had no effect on antibody detection. The bar-bourin moiety of BLAH6 was replaced with each of four sequences: Pep I (VCKGDWPC); Pep II (VCRGDWPC); Pep III (barbourin 41–54); and Pep IV (LPSPGDWR). The corresponding fusion proteins were tested for their ability to inhibit ADP-induced platelet aggregation. Pep III-LAH6 inhibited neither rabbit nor human platelets. Pep I-LAH6 and Pep IV-LAH6 inhibited rabbit platelet aggregation as effectively as BLAH6, but Pep IV-LAH6 did not inhibit human platelet aggregation. Pep I-LAH6 and Pep II LAH6 inhibited human platelet aggregation with IC50s 10– and 20-fold higher than BLAH6. Cross-immunoprecipitation assays with human platelet lysates confirmed that all proteins and peptides interacted with the platelet integrin αIIbβ3, but with greatly varying affinities. Our results suggest that the antiplatelet activity of BLAH6 can be retained in albumin fusion proteins in which smaller peptides replace the barbourin domain; these proteins may be less immunogenic than BLAH6.

Keywords

Platelets - aggregation - disintegrin - peptides - albumin
 

  • References

  • 1 Willoughby S, Holmes A, Loscalzo J. Platelets and cardiovascular disease. Eur J Cardiovasc Nurs 2002; 1: 273-88.
    CrossrefPubMedGoogle Scholar
  • 2 Weiss HJ. Flow-related platelet deposition on subendothelium. Thromb Haemost 1995; 74: 117-22.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110: 673-87.
    CrossrefPubMedGoogle Scholar
  • 4 Fullard JF. The role of the platelet glycoprotein IIb/ IIIa in thrombosis and haemostasis. Curr Pharm Des 2004; 10: 1567-76.
    CrossrefPubMedGoogle Scholar
  • 5 Plow EF, Byzova T. The biology of glycoprotein IIb-IIIa. Coron Artery Dis 1999; 10: 547-51.
    CrossrefPubMedGoogle Scholar
  • 6 Hanson J, de Leval X, David JL. et al. Progress in the field of GPIIb/IIIa antagonists. Curr Med Chem Cardiovasc Hematol Agents 2004; 2: 157-67.
    CrossrefPubMedGoogle Scholar
  • 7 Rosove MH. Platelet glycoprotein IIb/IIIa inhibitors. Best Pract Res Clin Haematol 2004; 17: 65-76.
    CrossrefPubMedGoogle Scholar
  • 8 Scarborough RM, Rose JW, Hsu MA. et al. Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem 1991; 266: 9359-62.
    PubMedGoogle Scholar
  • 9 Scarborough RM, Naughton MA, Teng W. et al. Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb- IIIa. J Biol Chem 1993; 268: 1066-73.
    PubMedGoogle Scholar
  • 10 Scarborough RM. Development of eptifibatide. Am Heart J 1999; 138: 1093-104.
    CrossrefPubMedGoogle Scholar
  • 11 Syed S, Schuyler PD, Kulczycky M. et al. Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin. Blood 1997; 89: 3243-52.
    PubMedGoogle Scholar
  • 12 Sheffield WP, Smith IJ, Syed S. et al. Prolonged in vivo anticoagulant activity of a hirudin-albumin fusion protein secreted from Pichia pastoris. Blood Coagul Fibrinolysis 2001; 12: 433-43.
    CrossrefPubMedGoogle Scholar
  • 13 Marques JA, George JK, Smith IJ. et al. A barbourin- albumin fusion protein that is slowly cleared in vivo retains the ability to inhibit platelet aggregation in vitro. Thromb Haemost 2001; 86: 902-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 McCollam PL, Foster DA, Riesmeyer JS. Cost and effectiveness of glycoprotein IIb/IIIa-receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Am J Health Syst Pharm 2003; 60: 1251-6.
    PubMedGoogle Scholar
  • 15 Leung VW, Sunderji R, Zed PJ. et al. Switching from abciximab to eptifibatide for percutaneous coronary interventions: a local analysis (SWAP study). Can J Cardiol 2003; 19: 809-14.
    PubMedGoogle Scholar
  • 16 Kobayashi K, Nakamura N, Sumi A. et al. The development of recombinant human serumalbumin. Ther Apher 1998; 2: 257-62.
    CrossrefPubMedGoogle Scholar
  • 17 McCurdy TR, Gataiance S, Eltringham-Smith LJ. et al. Acovalently linked recombinant albumin dimer is more rapidly cleared in vivo than arewild-type andmutant C34A albumin. J Lab Clin Med 2004; 143: 115-24.
    CrossrefPubMedGoogle Scholar
  • 18 Kelton JG, Smith JW, Horsewood P. et al. Gova/balloantigen system on human platelets. Blood 1990; 75: 2172-6.
    PubMedGoogle Scholar
  • 19 Smith JW, Kelton JG, Horsewood P. et al. Platelet specific alloantigens on the platelet glycoprotein Ia/IIa complex. Br J Haematol 1989; 72: 534-8.
    CrossrefPubMedGoogle Scholar
  • 20 Bhakta V, Begbie ME, Gupta A. et al. Heparin cofactor II is more sensitive than antithrombin to secretory impairment arising from mutations introduced into its carboxy-terminal region. Thromb Res 2004; 113: 163-73.
    CrossrefPubMedGoogle Scholar
  • 21 Markwell MA. A new solid-state reagent to iodinate proteins. I. Conditions for the efficient labeling of antiserum. Anal Biochem 1982; 125: 427-32.
    CrossrefPubMedGoogle Scholar
  • 22 Sheffield WP, Blajchman MA. Amino acid substitutions of the P2 residue of human antithrombin that either enhance or impair function. Thromb Res 1994; 75: 293-305.
    CrossrefPubMedGoogle Scholar
  • 23 Moriguchi A, Aoki T, Mihara K. et al. Antithrombotic effects of FK419, a novel nonpeptide platelet GPIIb/IIIa antagonist, in a guinea pig photochemically induced middle cerebral artery thrombosis model: comparison with ozagrel and argatroban. J Pharmacol Exp Ther 2004; 308: 1094-101.
    PubMedGoogle Scholar
  • 24 Hayashi Y, Katada J, Sato Y. et al. Discovery and structure--activity relationship studies of a novel and specific peptide motif, Pro-X-X-X-Asp-X, as a platelet fibrinogen receptor antagonist. Bioorg Med Chem 1998; 6: 355-64.
    CrossrefPubMedGoogle Scholar
  • 25 Brake AJ, Merryweather JP, Coit DG. et al. Alphafactor- directed synthesis and secretion of mature foreign proteins in Saccharomyces cerevisiae. Proc Natl Acad Sci U SA 1984; 81: 4642-6.
    CrossrefPubMedGoogle Scholar
  • 26 Lorenz TJ, Macdonald F, Kitt MM. Nonimmunogenicity of eptifibatide, a cyclic heptapeptide inhibitor of platelet glycoprotein IIb-IIIa. Clin Ther 1999; 21: 128-37.
    CrossrefPubMedGoogle Scholar
  • 27 Swenson S, Costa F, Minea R. et al. Intravenous liposomal delivery of the snake venom disintegrin contortrostatin limits breast cancer progression. Mol Cancer Ther 2004; 3: 499-511.
    PubMedGoogle Scholar
  • 28 Curtis BR, Swyers J, Divgi A. et al. Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood 2002; 99: 2054-9.
    CrossrefPubMedGoogle Scholar
  • 29 Kereiakes DJ, Runyon JP, Broderick TM. et al. IIb's are not IIb's. Am J Cardiol 2000; 85: 23C-31C.
    PubMedGoogle Scholar
  • 30 Shin J, Hong SY, Chung K. et al. Solution structure of a novel disintegrin, salmosin, from Agkistrondon halys venom. Biochemistry 2003; 42: 14408-15.
    CrossrefPubMedGoogle Scholar
  • 31 Smith KJ, Jaseja M, Lu X. et al. Three-dimensional structure of the RGD-containing snake toxin albolabrin in solution, based on 1HNMRspectroscopy and simulated annealing calculations. Int J Pept Protein Res 1996; 48: 220-8.
    PubMedGoogle Scholar
  • 32 Huang TF. What have snakes taught us about integrins?. Cell Mol Life Sci 1998; 54: 527-40.
    CrossrefPubMedGoogle Scholar
  • 33 Harfenist EJ, Packham MA, Mustard JF. Effects of the cell adhesion peptide, Arg-Gly-Asp-Ser, on responses of washed platelets from humans, rabbits, and rats. Blood 1988; 71: 132-6.
    PubMedGoogle Scholar